噻托溴铵联合舒利迭治疗难治性哮喘的临床观察  

Clinical Observation of Tiotropium Combined with Seretide in the Treatment of Refractory Asthma

作　　者：朱永健[1] 

机构地区：[1]海门市中医院,江苏海门226100

出　　处：《中外医学研究》2016年第14期27-29,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:比较噻托溴铵联合舒利迭与氨茶碱联合舒利迭治疗难治性哮喘的有效性。方法:选择2013年1月-2015年5月在本院住院的哮喘患者36例为研究对象,将其按随机数字表法分成治疗组和对照组,每组各18例。治疗组使用噻托溴铵联合舒利迭(50/500)、对照组使用氨茶碱联合舒利迭(50/500)分别治疗2周,观察两组患者治疗前后临床症状和肺功能的改变。结果:两组患者临床症状和肺功能均较治疗前显著改善(P<0.05),但治疗组改善情况优于对照组,比较差异均有统计学意义(P<0.05)。结论:噻托溴铵联合舒利迭(50/500)治疗难治性哮喘能更有效地改善临床症状和肺功能。Objective：To compare the efficiency of Tiotropium combined with Seretide（50/500） and Aminophylline combined with Seretide（50/500） on patients with refractory asthma.Method：Tirty-six patients with refractory asthma hospitalized in our hospital from January 2013 to May 2015 were selected and divided into the therapy group and the control group according to the random number table,18 patients in each group.The therapy group was treated with Tiotropium combined with Seretide（50/500） and the cotrol group with Aminophylline combined with Seretide（50/500） for 2 weeks.The clinical symptoms and pulmonary function before and after the treatment were observed.Result：The clinical symptoms and pulmonary function of the two groups after treatment were both better than before,but the improvement of the therapy group was more pronounced than in the control group,the differences were statistically significant（P〈0.05）. Conclusion：The treatment of Tiotropium combined with Seretide is a very effective way for patients with refractory asthma.

关 键 词：噻托溴铵 舒利迭 难治性哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]